Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.84 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.84 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874247 | 1.00 | CCR5 (0.90) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL2177194 | 0.91 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL4576508 | 0.91 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL1053748 | 0.91 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611449 | 0.91 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL51991 | 0.91 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL20451355 | 0.91 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL334506 | 0.91 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL3874242 | 0.89 | CCR5 (0.71) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL16276174 | 0.88 | CCR5 (0.88) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499098-A1 | METHODS OF TREATING A SUBJECT FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) AND COMPOSITIONS FOR USE IN THE SAME | IncellDx, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| EP-4469160-A1 | METHODS OF TREATING A SUBJECT FOR LONG-HAUL COVID-19, AND COMPOSITIONS FOR USE IN THE SAME | IncellDx, Inc. (US) | 2024-12-04 | — | — | EP | claimed |
| WO-2023192362-A1 | METHODS OF TREATING A SUBJECT FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023192361-A1 | METHODS OF TREATING A SUBJECT FOR FIBROMYALGIA AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023146812-A1 | METHODS OF TREATING A SUBJECT FOR LONG-HAUL COVID-19, AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| US-20250205220-A1 | Methods of Treating a Subject for Post-Treatment Lyme Disease (PTLD) and Compositions for Use in the Same | INCELLDX, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250205209-A1 | Methods of Treating a Subject for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Compositions for Use in The Same | INCELLDX, INC. | 2025-06-26 | — | — | US | disclosed |
| EP-4499098-A1 | METHODS OF TREATING A SUBJECT FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) AND COMPOSITIONS FOR USE IN THE SAME | IncellDx, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4469160-A1 | METHODS OF TREATING A SUBJECT FOR LONG-HAUL COVID-19, AND COMPOSITIONS FOR USE IN THE SAME | IncellDx, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023192362-A1 | METHODS OF TREATING A SUBJECT FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192361-A1 | METHODS OF TREATING A SUBJECT FOR FIBROMYALGIA AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023146812-A1 | METHODS OF TREATING A SUBJECT FOR LONG-HAUL COVID-19, AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205220-A1 | Methods of Treating a Subject for Post-Treatment Lyme Disease (PTLD) and Compositions for Use in the Same | CCR5, CCL5, CCL11 | CCR5 1/4885KCNH2 4880/4885CYP3A4 2753/4885 |
| US-20250205209-A1 | Methods of Treating a Subject for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Compositions for Use in The Same | CCR5, CCL5, CCL11 | CCR5 1/4885KCNH2 4746/4885CYP3A4 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.